<p>根據公司在最近向證券交易委員會提交的 13F 文件，Tredje AP fonden 在第四季度購買了 Jazz Pharmaceuticals PLC（納斯達克代碼：JAZZ - 免費報告）股票的新頭寸。這家機構投資者購買了 43,200 股這家專業製藥公司的股票，價值約為 7,344,000 美元。Tredje AP fonden 在最近一個季度末持有約 0.07% 的 Jazz Pharmaceuticals。</p>
<p>獲取 <strong>Jazz Pharmaceuticals</strong> 警報：</p>
<ul>
<li>Zymeworks 為長期投資者提供希望</li>
</ul>
<p>其他幾家大型投資者也增加或減少了對該公司的持股。Dimensional Fund Advisors LP 在第三季度將其在 Jazz Pharmaceuticals 的持股增加了 11.8%。Dimensional Fund Advisors LP 目前持有 2,836,652 股這家專業製藥公司的股票，價值 373,855,000 美元，此前在上個季度又購買了 298,815 股。Capital World Investors 在第三季度將其在 Jazz Pharmaceuticals 的持股增加了 0.4%。Capital World Investors 目前持有 2,554,867 股這家專業製藥公司的股票，價值 336,731,000 美元，此前在上個季度又購買了 10,345 股。Ameriprise Financial Inc. 在第二季度將其在 Jazz Pharmaceuticals 的持股增加了 11.4%。Ameriprise Financial Inc. 目前持有 1,867,399 股這家專業製藥公司的股票，價值 198,159,000 美元，此前在上個季度又購買了 191,637 股。摩根大通在第三季度將其在 Jazz Pharmaceuticals 的持股增加了 8.5%。摩根大通目前持有 1,867,159 股這家專業製藥公司的股票，價值 246,092,000 美元，此前在上個季度又購買了 145,865 股。最後，Vestal Point Capital LP 在第二季度以 127,344,000 美元的價格獲得了 Jazz Pharmaceuticals 的新頭寸。機構投資者和對沖基金持有該公司 89.14% 的股票。</p>
<h2>分析師升級和降級</h2>
<p>JAZZ 最近成為幾份研究報告的主題。Raymond James Financial 在 5 月 6 日的報告中重申了對 Jazz Pharmaceuticals 的 &#34;跑贏大盤&#34; 評級，並設定了 239.00 美元的目標價。巴克萊在 5 月 6 日的報告中將 Jazz Pharmaceuticals 的目標價從 225.00 美元提高至 234.00 美元，並給予該股票 &#34;增持&#34; 評級。Leerink Partners 在 4 月 22 日的報告中將 Jazz Pharmaceuticals 的目標價從 215.00 美元提高至 225.00 美元，並給予該股票 &#34;跑贏大盤&#34; 評級。TD Cowen 在 5 月 6 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 220.00 美元提高至 275.00 美元，並給予該公司 &#34;買入&#34; 評級。最後，加拿大皇家銀行在 5 月 6 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 195.00 美元提高至 258.00 美元，並給予該公司 &#34;跑贏大盤&#34; 評級。一位研究分析師對該股票給予了強烈買入評級，十五位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 238.00 美元。</p>
<ul>
<li>頂級大麻股票：投資機會豐富（你並沒有錯過機會）</li>
</ul>
<p><strong>閲讀我們對 Jazz Pharmaceuticals 的最新分析</strong></p>
<h2>Jazz Pharmaceuticals 的內部交易</h2>
<p>在其他 Jazz Pharmaceuticals 的新聞中，首席會計官 Patricia Carr 於 3 月 9 日星期一出售了 1,287 股該股票。股票以平均價格 182.94 美元出售，總價值為 235,443.78 美元。出售完成後，首席會計官持有該公司 6,512 股，價值 1,191,305.28 美元。這筆交易代表了他們持股的 16.50% 的減少。該出售在與 SEC 的法律文件中披露，鏈接可通過此處獲取。此外，執行副總裁 Neena M. Patil 於 2 月 26 日星期四出售了 55,600 股該股票。股票以平均價格 191.56 美元出售，總交易額為 10,650,736.00 美元。交易完成後，執行副總裁直接持有該公司 56,862 股，價值 10,892,484.72 美元。這筆交易代表了他們持股的 49.44% 的減少。該出售的披露在 SEC 文件中可獲得。在上個季度，內部人士出售了價值 14,180,486 美元的 74,015 股公司股票。公司內部人士持有 4.30% 的股票。</p>
<h2>Jazz Pharmaceuticals 股票表現</h2>
<p>JAZZ 股票在星期三開盤價為 237.45 美元。該股票的市值為 149 億美元，市盈率為 -11,866.57，市盈率/增長比率為 0.41，貝塔係數為 0.27。該公司的債務與股本比率為 0.95，流動比率為 2.04，速動比率為 1.85。該公司有 50 天的移動平均價格為 199.21 美元，200 天的移動平均價格為 178.13 美元。Jazz Pharmaceuticals PLC 的一年低點為 105.00 美元，一年高點為 238.55 美元。</p>
<p>Jazz Pharmaceuticals（納斯達克代碼：JAZZ - 獲取免費報告）最後一次公佈季度財報是在 3 月 31 日星期二。這家專業製藥公司報告該季度每股收益為 6.34 美元。該公司在該季度的收入為 10.7 億美元。Jazz Pharmaceuticals 的淨利潤率為 0.66%，股本回報率為 14.56%。作為一個整體，股票分析師預測 Jazz Pharmaceuticals PLC 在本年度將發佈 20.75 美元的每股收益。</p>
<h2>Jazz Pharmaceuticals 簡介</h2>
<p>（免費報告）</p>
<p>Jazz Pharmaceuticals plc 是一家全球生物製藥公司，專注於開發和商業化神經科學和腫瘤學領域的療法。該公司的研發工作針對睡眠障礙、血液惡性腫瘤、罕見神經疾病和實體腫瘤等未滿足的醫療需求。Jazz 的產品組合包括治療嗜睡症、肝靜脈阻塞病、急性髓性白血病及其他嚴重疾病的療法。</p>
<p>Jazz Pharmaceuticals 的旗艦產品包括 Xyrem®（氧丁酸鈉）和 Xywav®（氧丁酸鈣、鎂、鉀和鈉），用於治療嗜睡症患者的肌肉無力發作和白天過度嗜睡。</p>
<h2>另請參見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Jazz Pharmaceuticals</li>
<li>HIVE 利用電力進行 AI 轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動向</li>
<li>Brady Corp 啓動了一次大規模的 AI 驅動突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大的機會</li>
</ul>
<p><strong>想看看其他對 JAZZ 感興趣的對沖基金持有什麼嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Jazz Pharmaceuticals 嗎？</h2>
<p>在考慮 Jazz Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Jazz Pharmaceuticals 並不在名單上。</p>
<p>雖然 Jazz Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

爵士制藥

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

醫療業 ETF - Vanguard

IBBQ

<p>根據最近的 SEC 文件，第三支柱養老金基金在第四季度收購了 43,200 股爵士製藥（Jazz Pharmaceuticals PLC，NASDAQ:JAZZ），價值約 734 萬美元。其他機構投資者也增加了他們的持股，維度基金顧問（Dimensional Fund Advisors）將持股提高了 11.8%。分析師對爵士製藥給予了 “適度買入” 的評級，平均目標價格為 238.00 美元</p>

<p>Tredje AP fonden bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor bought 43,200 shares of the specialty pharmaceutical company's stock, valued at approximately $7,344,000. Tredje AP fonden owned about 0.07% of Jazz Pharmaceuticals at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據公司在最近向證券交易委員會提交的 13F 文件，Tredje AP fonden 在第四季度購買了 Jazz Pharmaceuticals PLC（納斯達克代碼：JAZZ - 免費報告）股票的新頭寸。這家機構投資者購買了 43,200 股這家專業製藥公司的股票，價值約為 7,344,000 美元。Tredje AP fonden 在最近一個季度末持有約 0.07% 的 Jazz Pharmaceuticals。</p>
</div><p>Get <strong>Jazz Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Jazz Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>Zymeworks 為長期投資者提供希望</li>
</ul>
</div><p>Several other large investors have also added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock worth $373,855,000 after purchasing an additional 298,815 shares during the last quarter. Capital World Investors boosted its holdings in Jazz Pharmaceuticals by 0.4% during the third quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company's stock worth $336,731,000 after purchasing an additional 10,345 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock worth $198,159,000 after purchasing an additional 191,637 shares during the last quarter. JPMorgan Chase &amp; Co. boosted its holdings in Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase &amp; Co. now owns 1,867,159 shares of the specialty pharmaceutical company's stock worth $246,092,000 after purchasing an additional 145,865 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals during the second quarter worth $127,344,000. Institutional investors and hedge funds own 89.14% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家大型投資者也增加或減少了對該公司的持股。Dimensional Fund Advisors LP 在第三季度將其在 Jazz Pharmaceuticals 的持股增加了 11.8%。Dimensional Fund Advisors LP 目前持有 2,836,652 股這家專業製藥公司的股票，價值 373,855,000 美元，此前在上個季度又購買了 298,815 股。Capital World Investors 在第三季度將其在 Jazz Pharmaceuticals 的持股增加了 0.4%。Capital World Investors 目前持有 2,554,867 股這家專業製藥公司的股票，價值 336,731,000 美元，此前在上個季度又購買了 10,345 股。Ameriprise Financial Inc. 在第二季度將其在 Jazz Pharmaceuticals 的持股增加了 11.4%。Ameriprise Financial Inc. 目前持有 1,867,399 股這家專業製藥公司的股票，價值 198,159,000 美元，此前在上個季度又購買了 191,637 股。摩根大通在第三季度將其在 Jazz Pharmaceuticals 的持股增加了 8.5%。摩根大通目前持有 1,867,159 股這家專業製藥公司的股票，價值 246,092,000 美元，此前在上個季度又購買了 145,865 股。最後，Vestal Point Capital LP 在第二季度以 127,344,000 美元的價格獲得了 Jazz Pharmaceuticals 的新頭寸。機構投資者和對沖基金持有該公司 89.14% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>JAZZ has been the subject of several recent research reports. Raymond James Financial restated an &#34;outperform&#34; rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Barclays increased their target price on shares of Jazz Pharmaceuticals from $225.00 to $234.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, May 6th. Leerink Partners increased their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, April 22nd. TD Cowen increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $238.00.</p>
<div class="lb-trans"><p>JAZZ 最近成為幾份研究報告的主題。Raymond James Financial 在 5 月 6 日的報告中重申了對 Jazz Pharmaceuticals 的 &#34;跑贏大盤&#34; 評級，並設定了 239.00 美元的目標價。巴克萊在 5 月 6 日的報告中將 Jazz Pharmaceuticals 的目標價從 225.00 美元提高至 234.00 美元，並給予該股票 &#34;增持&#34; 評級。Leerink Partners 在 4 月 22 日的報告中將 Jazz Pharmaceuticals 的目標價從 215.00 美元提高至 225.00 美元，並給予該股票 &#34;跑贏大盤&#34; 評級。TD Cowen 在 5 月 6 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 220.00 美元提高至 275.00 美元，並給予該公司 &#34;買入&#34; 評級。最後，加拿大皇家銀行在 5 月 6 日的研究報告中將 Jazz Pharmaceuticals 的目標價從 195.00 美元提高至 258.00 美元，並給予該公司 &#34;跑贏大盤&#34; 評級。一位研究分析師對該股票給予了強烈買入評級，十五位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 238.00 美元。</p>
</div><ul>
<li>Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game)</li>
</ul>
<div class="lb-trans"><ul>
<li>頂級大麻股票：投資機會豐富（你並沒有錯過機會）</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Jazz Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Jazz Pharmaceuticals 的最新分析</strong></p>
</div><h2>Insider Transactions at Jazz Pharmaceuticals</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 的內部交易</h2>
</div><p>In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,287 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the sale, the chief accounting officer owned 6,512 shares in the company, valued at $1,191,305.28. This trade represents a 16.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 55,600 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the completion of the transaction, the executive vice president directly owned 56,862 shares in the company, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 74,015 shares of company stock valued at $14,180,486. 4.30% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Jazz Pharmaceuticals 的新聞中，首席會計官 Patricia Carr 於 3 月 9 日星期一出售了 1,287 股該股票。股票以平均價格 182.94 美元出售，總價值為 235,443.78 美元。出售完成後，首席會計官持有該公司 6,512 股，價值 1,191,305.28 美元。這筆交易代表了他們持股的 16.50% 的減少。該出售在與 SEC 的法律文件中披露，鏈接可通過此處獲取。此外，執行副總裁 Neena M. Patil 於 2 月 26 日星期四出售了 55,600 股該股票。股票以平均價格 191.56 美元出售，總交易額為 10,650,736.00 美元。交易完成後，執行副總裁直接持有該公司 56,862 股，價值 10,892,484.72 美元。這筆交易代表了他們持股的 49.44% 的減少。該出售的披露在 SEC 文件中可獲得。在上個季度，內部人士出售了價值 14,180,486 美元的 74,015 股公司股票。公司內部人士持有 4.30% 的股票。</p>
</div><h2>Jazz Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 股票表現</h2>
</div><p>Shares of JAZZ stock opened at $237.45 on Wednesday. The stock has a market cap of $14.90 billion, a P/E ratio of -11,866.57, a P/E/G ratio of 0.41 and a beta of 0.27. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The company has a fifty day moving average price of $199.21 and a two-hundred day moving average price of $178.13. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $238.55.</p>
<div class="lb-trans"><p>JAZZ 股票在星期三開盤價為 237.45 美元。該股票的市值為 149 億美元，市盈率為 -11,866.57，市盈率/增長比率為 0.41，貝塔係數為 0.27。該公司的債務與股本比率為 0.95，流動比率為 2.04，速動比率為 1.85。該公司有 50 天的移動平均價格為 199.21 美元，200 天的移動平均價格為 178.13 美元。Jazz Pharmaceuticals PLC 的一年低點為 105.00 美元，一年高點為 238.55 美元。</p>
</div><p>Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current year.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals（納斯達克代碼：JAZZ - 獲取免費報告）最後一次公佈季度財報是在 3 月 31 日星期二。這家專業製藥公司報告該季度每股收益為 6.34 美元。該公司在該季度的收入為 10.7 億美元。Jazz Pharmaceuticals 的淨利潤率為 0.66%，股本回報率為 14.56%。作為一個整體，股票分析師預測 Jazz Pharmaceuticals PLC 在本年度將發佈 20.75 美元的每股收益。</p>
</div><h2>Jazz Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc 是一家全球生物製藥公司，專注於開發和商業化神經科學和腫瘤學領域的療法。該公司的研發工作針對睡眠障礙、血液惡性腫瘤、罕見神經疾病和實體腫瘤等未滿足的醫療需求。Jazz 的產品組合包括治療嗜睡症、肝靜脈阻塞病、急性髓性白血病及其他嚴重疾病的療法。</p>
</div><p>Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals 的旗艦產品包括 Xyrem®（氧丁酸鈉）和 Xywav®（氧丁酸鈣、鎂、鉀和鈉），用於治療嗜睡症患者的肌肉無力發作和白天過度嗜睡。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參見</h2>
</div><ul>
<li>Five stocks we like better than Jazz Pharmaceuticals</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Jazz Pharmaceuticals</li>
<li>HIVE 利用電力進行 AI 轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動向</li>
<li>Brady Corp 啓動了一次大規模的 AI 驅動突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大的機會</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JAZZ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 JAZZ 感興趣的對沖基金持有什麼嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=JAZZ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Jazz Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Jazz Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Jazz Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Jazz Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Jazz Pharmaceuticals 並不在名單上。</p>
</div><p>While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Jazz Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

43,200 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Tredje AP fonden

Market Beat

Invesco Nasdaq Biotechnology ETF

Zymeworks

阿默普萊斯金融

摩根大通

瑞傑金融

巴克萊銀行

Toronto Dominion Bank

加拿大皇家銀行

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Tredje AP fonden 購入了爵士製藥 PLC $JAZZ 的 43,200 股股票